Lv71
5000 积分 2024-01-08 加入
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms
3小时前
已完结
Early-Phase Oncology Trials: Why So Many Designs?
5天前
已完结
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms
1个月前
已完结
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
2个月前
已完结
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms
2个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
2个月前
已完结
Chronic lymphocytic leukaemia
3个月前
已完结
From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment
3个月前
已完结
皖公网安备34019202002308
